ConcertAI, an oncology evidence and AI SaaS technology company, has launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform designed to automate and optimize the full clinical trial lifecycle. ACT combines real-world data and proprietary datasets with advanced AI workflows to help trial sponsors and contract research organizations shorten study timelines by an estimated 10 to 20 months.
The platform targets challenges in clinical research, including patient recruitment delays, complex protocols, and fragmented data that often result in costly trial amendments. By embedding AI-based probability forecasting into trial design and execution, ACT enables teams to anticipate risks earlier and improve the likelihood of meeting enrollment and endpoint objectives.Built on ConcertAI’s CARAai agentic AI platform, ACT deploys specialized assistants to automate tasks such as protocol development, feasibility analysis, site selection, competitive trial assessment, and patient matching.
Eron Kelly, Chief Executive Officer of ConcertAI, said, “Sponsors don’t need another isolated tool; they need an end-to-end solution that identifies bottlenecks and guides next steps.” He added that ACT provides “greater control and clear visibility throughout the entire study lifecycle.” Industry analysts have also highlighted the approach. According to Frost & Sullivan, “ConcertAI is one of the key competitors in utilizing generative and agentic AI and proprietary real-world data to transform clinical trial operations,” citing gains in patient screening, site optimization, and workflow automation. ConcertAI reports that ACT can reduce study design timelines and protocol amendments by up to 50%, while significantly accelerating site activation and recruitment.